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Abstract
Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by Junı ´n virus (JUNV), a member of the
arenaviridae family. Although a recently introduced live attenuated vaccine has proven to be effective, AHF remains a
potentially lethal infection. Like in other viral hemorrhagic fevers (VHF), AHF patients present with fever and hemorrhagic
complications. Although the causes of the bleeding are poorly understood, impaired hemostasis, endothelial cell
dysfunction and low platelet counts have been described. Thrombocytopenia is a common feature in VHF syndromes, and it
is a major sign for its diagnosis. However, the underlying pathogenic mechanism has not yet been elucidated. We
hypothesized that thrombocytopenia results from a viral-triggered alteration of the megakaryo/thrombopoiesis process.
Therefore, we evaluated the impact of JUNV on megakaryopoiesis using an in vitro model of human CD34
+ cells stimulated
with thrombopoietin. Our results showed that CD34
+ cells are infected with JUNV in a restricted fashion. Infection was
transferrin receptor 1 (TfR1)-dependent and the surface expression of TfR1 was higher in infected cultures, suggesting a
novel arenaviral dissemination strategy in hematopoietic progenitor cells. Although proliferation, survival, and commitment
in JUNV-infected cultures were normal, viral infection impaired thrombopoiesis by decreasing in vitro proplatelet formation,
platelet release, and P-selectin externalization via a bystander effect. The decrease in platelet release was also TfR1-
dependent, mimicked by poly(I:C), and type I interferon (IFN a/b) was implicated as a key paracrine mediator. Among the
relevant molecules studied, only the transcription factor NF-E2 showed a moderate decrease in expression in
megakaryocytes from either infected cultures or after type I IFN treatment. Moreover, type I IFN-treated megakaryocytes
presented ultrastructural abnormalities resembling the reported thrombocytopenic NF-E2
2/2 mouse phenotype. Our study
introduces a potential mechanism for thrombocytopenia in VHF and other diseases associated with increased bone marrow
type I IFN levels.
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Introduction
Viral hemorrhagic fever (VHF) is an acute systemic febrile
syndrome caused by a diverse group of RNA viruses from the
Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae viral families
[1–3]. Patients with this syndrome present with a combination of
fever, prostration, malaise, and differing degrees of hematological
complications [1,4]. When severe, patients with VHF can present
with generalized bleeding that results from alterations of the
vascular endothelium, blood coagulation components and platelet
levels [5–8]. Moreover, a plasma platelet aggregation inhibitor has
been described in patients with different types of VHF [9,10].
These findings suggest that different etiologic agents of VHF may
share common processes for disturbing hemostasis during
infection, leading to a systemic and frequently fatal disease. In
fact, thrombocytopenia is one of the most consistent findings
among human patients and experimental animal models of VHF,
and it is used as a major diagnostic feature in patients with VHF
[11,12]. However, the causes of the thrombocytopenia associated
with VHF remain poorly understood. In this connection,
disseminated intravascular coagulation (DIC) could explain
platelet consumption; nevertheless, the occurrence of DIC in
VHF infections is inconclusive, at least for the arenavirus family
[12]. Therefore, a high level of splenic sequestration or impaired
PLoS Pathogens | www.plospathogens.org 1 April 2010 | Volume 6 | Issue 4 | e1000847megakaryo/thrombopoiesis could be the major physiopathogenic
mechanisms responsible for the low platelet count.
We hypothesized that the thrombocytopenia observed in VHF
is the result of a viral-triggered alteration of the megakaryo/
thrombopoiesis process. Support for this hypothesis comes from
studies of experimental murine lymphocytic choriomeningitis virus
(LCMV) infection showing an association between thrombocyto-
penia and reduced megakaryocyte number at the bone marrow
level [13] and the observation that the reversible depression of
hematopoiesis during early LCMV infection is a direct effect of
IFN a/b [14]. In addition, megakaryocyte alterations were found
in patients with Argentine hemorrhagic fever (AHF) [15] and
Dengue [16], and in experimental studies involving Junı ´n virus
(JUNV) infection of guinea pigs [17] and the primates Callithrix
jacchus [18] and Rhesus macaques [19].
AHF is an endemo-epidemic disease caused by JUNV, a member
of the Arenaviridae family. Although a recently introduced live
attenuated vaccine has proven to be effective, AHF remains a
potentially lethal infection and JUNV is considered to be a potential
biological weapon [20]. Relative to other etiologic agents of VHF,
JUNV is a suitable model for studying VHF pathogenesis due to the
availability of a relatively large amount of data from both human
and experimental infections, viral strains with known nucleotide
sequences, several monoclonal antibodies against various compo-
nents of the virus and an effective protective vaccine [21–23].
In this study, we evaluated whether the different megakaryo-
poiesi/thrombopoiesis stages (including proliferation, commit-
ment, maturation, proplatelet formation and platelet release and
function) are affected by JUNV infection of hematopoietic
progenitor cells. Our results showed that human CD34
+ cells are
infected by JUNV. Furthermore, we have identified selective
inhibition of platelet release involving transferrin receptor 1 (TfR1)
and type I IFN (IFN a/b) as paracrine mediators.
Results
An in vitro model of megakaryopoiesis
To analyze whether the thrombocytopenia observed in AHF
patients could be the result of altered megakaryopoiesis, we used
an in vitro model of human CD34
+ cells stimulated with
thrombopoietin (TPO). Under our culture conditions, TPO
stimulation promoted proliferation, an increase in cell size and
CD41 expression and a decrease in CD34 expression (Figure 1A–
C). The formation of long, branching processes called proplatelets,
which showed small platelet-sized swellings that represented the
developing platelets [24], was also observed on days 11–12 of
culture (Figure 1E). In agreement with previous reports, platelets
were released into the culture medium [25]. The kinetics of in vitro
platelet release started at days 11–13, peaked at day 17 and
declined after 21 days, correlating with the apoptosis/senescence
of the cell culture (Figure 1D).
JUNV infection selectively impairs in vitro platelet
generation
Figure 2 shows that JUNV infection of CD34
+ cells influenced
neither their apoptosis, their proliferation rate, their maturation
(CD42b
+ and ploidy levels), megakaryocyte differentiation
(CD41
+) nor the clonogenic ability of megakaryocyte progenitors.
Surprisingly, JUNV infection induced a significant decrease in
both proplatelet formation (Figure 3A and B) and platelet release
(Figure 3C and D) when compared to mock- or UV-irradiated
JUNV-infected cultures. These results indicate that viral infection
selectively hindered two key steps in thrombopoiesis that represent
the last stage of the megakaryocyte lifespan, and viral replication
was necessary to observe this effect.
To gain a deeper insight into the platelet biology of JUNV-
infected cultures, we next explored the ability of platelets to
express P-selectin. Our flow cytometric analysis showed that
11.163.3% of resting platelets generated in UV-irradiated JUNV-
infected cultures expressed P-selectin on their surface, and after
thrombin stimulation this rose to 49.264.1% (n=3, p,0.05). In
contrast, P-selectin externalization was significantly reduced in
platelets derived from JUNV-infected cultures (3.361.3% and
13.564.1% for resting and thrombin-stimulated samples, respec-
tively, n=3).
Susceptibility of CD34
+ cells to JUNV infection
As shown in Figure 4A, CD34
+ cells were susceptible to JUNV
infection. At ten days post-infection (p.i.), RNA from JUNV-
inoculated CD34
+ cells displayed a fragment of the viral genome,
while RNA from cultures exposed to the UV-irradiated JUNV
strain did not. Immunofluorescence and flow cytometric studies
revealed that 4.160.2 and 4.960.5% of the cells were infected,
respectively (Figure 4B and C). These results were in sharp
contrast to the 68611% of JUNV-positive cells observed after in-
parallel infection of the susceptible Vero-76 cell line [26]
(Figure 4D). Although some megakaryocytes were clearly positive
for JUNV, most of the susceptible cells were not (Figure 4B and C).
These results suggest that viral infection per se is not a direct cause
of the observed reduced thrombopoiesis.
Role of TfR1 in JUNV infection and impaired platelet
production
In contrast to Lassa and other old world arenaviruses, which
use a-dystroglycan to infect cells, it has been reported that TfR1
is the cellular receptor for several new world arenaviruses,
including JUNV [27]. Therefore, we evaluated the expression of
this protein in JUNV-infected cultures. Interestingly, TfR1
expression was significantly higher in JUNV-infected CD34
+
cells compared to UV-irradiated JUNV-infected cells, suggest-
ing that JUNV infection promotes further infection (Figure 5A
and B).
Author Summary
Argentine hemorrhagic fever (AHF) is an endemo-epidemic
disease caused by Junı ´n virus (JUNV). Although a recently
introduced live attenuated vaccine has proven to be
effective, AHF remains a potentially lethal infection and
JUNV is considered to be a potential biological weapon. Like
other viral hemorrhagic fevers (VHF), AHF patients present
fever with a combination of neurological and bleeding
complications. Although the causes of the bleeding are
poorly understood, impaired hemostasis and endothelial cell
function as well as low platelet counts have been described.
In this study, we have examined the impact of JUNV on an
in vitro model of platelet production. We found that neither
infection of hematopoietic progenitors with JUNV nor
poly(I:C) (a double-stranded RNA that mimics viral infection)
affected cell survival or megakaryocyte generation. Howev-
er, these treatments triggered the main anti-viral cytokines
produced by host type I IFN (IFN a/b), which acted in a
paracrine fashion and led to abnormal platelet formation.
Thus, this study identifies type I IFN as a new regulator that
selectively affects the last steps of megakaryocyte lifespan,
and it suggests a potential mechanism for thrombocytope-
nia in AHF and other diseases associated with increased
bone marrow type I IFN levels.
IFN a/b Link JUNV Infection with Thrombocytopenia
PLoS Pathogens | www.plospathogens.org 2 April 2010 | Volume 6 | Issue 4 | e1000847Figure 1. Characterization of liquid cultures of human CD34
+ cells stimulated by TPO. CD34
+ cells (1610
4/ml) purified by
immunomagnetic positive selection were cultured in IMDM containing 5% human serum and TPO (25 ng/ml added at days one and seven of the cell
culture). At the indicated culture times, (A) total cell count was determined with a hemocytometer and (B) cell size was analyzed by flow cytometry.
(C) CD41 and CD34 expression were evaluated by labeling cells with specific mAbs or corresponding matched isotypes and establishing the
percentage of positive cells by flow cytometry analysis. (D) Platelet (Plt) count was evaluated by flow cytometry and cellular apoptosis was
determined by detecting nuclear morphological changes of cells stained with acridine orange and ethidium bromide by fluorescence microscopy. (E)
Culture morphology was assessed by phase contrast microscopy [original magnification 4506, except day 12 inset (12006)]. The values expressed in
panels A–D represent the mean 6 SEM of five independent experiments. Panel E shows a representative experiment of five similar replicates.
doi:10.1371/journal.ppat.1000847.g001
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infection, we next examined whether TfR1 has a role in JUNV
infection and in the inhibitory effect of JUNV on platelet release.
When CD34
+ cells were incubated with a specific monoclonal
antibody (mAb) against TfR1, neither viral antigens nor the
inhibitory effect of JUNV on the number of platelets generated
were observed (Figure 5C and D). In contrast, incubation with
anti-HLA-ABC (an irrelevant mAb) had no effect. Similar results
were obtained when TfR1 was first down-regulated by iron
overload. However, up-regulation of TfR1 levels by iron
deprivation did not modify the effect of JUNV on platelet
generation (Figure 5D). These results not only unveil a potential
new mechanism by which JUNV spreads its infection in
hematopoietic progenitor cells, but they also provide evidence
that the reduced thrombopoiesis is specifically related to JUNV
infection.
Involvement of the type I IFN pathway on JUNV-induced
impairment of platelet release
Because the number of infected cells was low and only a few
were positively identified as megakaryocytes, it was reasonable to
consider that the decrease in platelet release was most likely the
result of a bystander cell effect rather than a direct effect of JUNV
on megakaryocytes. Thus, to further study the biological effects of
viral infection on platelet release, we analyzed the effect of
poly(I:C), which mimics the double-stranded RNA (dsRNA)
product from the replicative cycle of most viruses [28]. Figure 6A
shows that the addition of poly(I:C) at early time points to TPO-
stimulated CD34
+ cell cultures significantly decreased platelet
release. Similarly to JUNV infection, this inhibition was not
related to apoptosis induction or a decrease in megakaryocyte
generation (data not shown). These results suggest that the
reduction in platelet release could be a more generalized effect
and may not be restricted to JUNV infection.
Because poly(I:C) is a potent inducer of IFN b release in vitro
and in vivo [29], we next tested if this was a functional
mechanism in our in vitro system. While UV-irradiated JUNV-
infected-CD34
+ cell cultures stimulated by TPO did not express
IFN b mRNA, increasing expression over time was observed in
JUNV-infected cultures (Figure 6B). Accordingly, 10 U/ml of
IFN b efficiently inhibited platelet release (Figure 6C). How-
ever, when used at concentrations of 100 U/ml or higher, it not
Figure 2. Influence of JUNV infection on cellular apoptosis, proliferation, clonogenic capacity and megakaryocyte development of
TPO-stimulated CD34
+ cells. CD34
+ cells were infected with JUNV at a MOI of one or the equivalent volume of UV-irradiated virus or Vero cell
supernatant (mock) for one hr at 37uC, washed, and then stimulated with TPO. (A) Apoptosis, (B) total cell count, (C) megakaryocyte colonies grown in
collagen-based serum-free medium containing 50 ng/ml TPO, percentages of (D) CD41
+ and (E) CD42b
+ cells and (F) ploidy distribution were
determined at the indicated days of culture, except for colonies and ploidy, which were counted after 12 or 14 days of culture, respectively. The
values represent the mean 6 SEM of four independent experiments.
doi:10.1371/journal.ppat.1000847.g002
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creased cell number (Figure 6D) without affecting the apoptosis
rate (data not shown). These results suggest that IFN b might
differentially regulate cellular responses, affecting only platelet
production at low levels but affecting the cell cycle at higher
levels. That IFN b was responsible for the JUNV-mediated
biological effect was further supported by the observation that
platelet production was restored to normal values in JUNV-
infected cultures when IFN b w a sb l o c k e db yan e u t r a l i z i n gA b
(Figure 6E). To the best of our knowledge, the expression of
type I IFN receptor in megakaryocytes has not been previously
described. Thus, we examined the presence of mRNAs in
purified megakaryocytes. RT-PCR studies revealed that
megakaryocyte precursors transcribe both subunits of the IFN
a/b receptor mRNAs (Figure 6F).
Because another general feature of the cells’ response to viral
infection is an increase in IFN a production, as a downstream
product of the IFN b pathway, this molecule was also studied.
Stimulation of CD34
+ cells with IFN a mimicked the results
obtained with IFN b (data not shown). These results were not
surprising bearing in mind that both IFNs are ligands for the same
receptor [30]. Overall, these results strongly indicate that the type
I IFN signaling pathway may have a key role in the defective
platelet release mediated by JUNV in vitro.
Figure 3. JUNV infection impairs proplatelet production and platelet release. CD34
+ cells were mock-infected or infected with UV-
irradiated JUNV or JUNV and then stimulated with TPO. (A) The number of megakaryocytes displaying proplatelets was determined at day 12 of the
culture by F-actin and nuclear staining with phalloidin-TRITC and DAPI, respectively, and examined by fluorescence microscopy. The values represent
the mean 6 SEM of four independent experiments. (B) A representative picture of a proplatelet-displaying megakaryocyte. (C) Plt count was
determined by flow cytometry. At different days, culture aliquots were stained with an anti-CD41-FITC mAb and the acquisition rate was fixed at 1 ml/
sec for 100 sec. Events were collected without gating using a log scale for size (FSC) and intracellular granularity (SSC). An analytical gate was
determined based on the scatter properties of peripheral blood platelets treated similarly. Culture-derived platelets were counted as CD41
+ events
with the same scatter properties as blood platelets. The values are expressed as platelets (610
5) and represent the mean 6 SEM of six independent
experiments. * indicates p,0.05 vs. UV-irradiated JUNV or mock. (D) A representative flow cytometric analysis 15 days after TPO stimulation.
doi:10.1371/journal.ppat.1000847.g003
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from type I IFN receptor knockout mice are more susceptible to
LCMV infection [14], we next explored the role of type I IFN in
JUNV infection. Figure 6G shows that the percentage of infected
cells increased from 5% to 10% when the biological activity of IFN
b was neutralized. However, recombinant IFN b did not modify
TfR1 expression (Figure 6H) suggesting that viral replication in
hematopoietic progenitor cells is controlled, at least in part, by
IFN b production in a TfR1-independent manner.
Mechanisms involved in JUNV inhibition of platelet
formation
Although the signaling pathways regulating thrombopoiesis are
still under study, Src kinases and several transcription factors have
been shown to be involved as regulators of this process [31]. To
clarify the mechanistic basis of the impaired platelet production in
infected cultures, we first determined whether Src kinases were
involved by using a specific inhibitor (PP2). Figure 7A shows that
although Src inhibition enhanced platelet release in control cells, it
did not prevent the JUNV-induced reduction in platelet number.
To examine the levels of relevant factors involved in
megakaryo/thrombopoiesis, we performed a semi-quantitative
RT-PCR assay. We found that the mRNAs of SOCS-1, SOCS-
3 and GATA-1, three molecules involved in the initial steps of
megakaryocyte development [32], were similar in JUNV- and UV-
irradiated JUNV-infected cultures. In contrast, NF-E2, the main
transcription factor regulating platelet biogenesis [33], was lower in
JUNV-infected samples (Figure 7B). In addition, the total amount
of NF-E2 protein was moderately but significantly diminished in
the megakaryocytic population by viral infection (Figure 7C).
Type I IFN decreases NF-E2 expression and induces
intrinsic megakaryocytic abnormalities
Having demonstrated that JUNV infection triggers the
production of type I IFN and impairs platelet formation, in the
next experiments we examined whether type I IFN was capable of
regulating the expression of NF-E2. The results showed that like
viral infection, the exposure of purified megakaryocytes to IFN b
(Figure 8A) or a (data not shown) resulted in lower NF-E2
expression compared to control samples.
Because NF-E2
2/2 mice lack circulating platelets and their
megakaryocytes show no cytoplasmic platelet formation [33], we
analyzed the effect of type I IFN on megakaryocytes at the
ultrastructural level. Electron microscopic studies revealed that in
contrast with control megakaryocytes, which had a lobulated
nucleus and abundant cytoplasm with a mature demarcation
membrane system (DMS), in the IFN b-treated cells the DMS was
almost absent and lacked organization and platelet territories
(Figure 8B). The nucleus looked normal and there was a large
cytoplasm, but the contents of the megakaryocyte were not evenly
Figure 4. JUNV replication in CD34
+ cells. CD34
+ cells were inoculated with UV-irradiated JUNV or JUNV and stimulated with TPO for ten days.
Viral replication was assayed by RT-PCR, immunofluorescence and flow cytometry. (A) RT-PCR studies. (B) To detect JUNV antigens by
immunofluorescence cells were washed, cytocentrifuged on silanized glasses, fixed, permeabilized and incubated first with a pool of specific mAbs
against JUNV and a rabbit-anti-human vWF polyclonal Ab to identify megakaryocytes, and then with FITC-conjugated anti-rabbit (green) and Cy3-
conjugated anti-mouse Igs (red). The slides were counterstained with DAPI and photographed at 10006magnification. (C) Cells were stained as in B
and then analyzed by flow cytometry. (D) As a positive control, JUNV-susceptible Vero-76 cells were inoculated with JUNV and seven days later were
stained with the pool of specific mAbs against JUNV followed by Cy3-anti-mouse Igs. Negative controls in B and C were performed by incubating cells
only with secondary Abs. Panels show a representative experiment of three similar replicates.
doi:10.1371/journal.ppat.1000847.g004
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granules and organelles. Finally, we observed patches of released
platelets that were produced only by megakaryocytes in the control
cultures. Interestingly, all these observations resemble the NF-
E2
2/2 megakaryocyte phenotype [33]. IFN a induced similar
ultrastructural abnormalities (data not shown).
Discussion
In this paper, we present evidence that JUNV infects
hematopoietic progenitors in a restricted fashion leading to a
significant inhibition of thrombopoiesis, including proplatelet
formation, platelet release and platelet function.
Previous studies of the effect of viral infection on megakaryo-
cytes derived from CD34
+ cells showed that human immunode-
ficiency virus (HIV), human herpesvirus 6 and human cytomeg-
alovirus negatively affected the survival, differentiation and/or
maturation of megakaryocyte progenitors [34–36]. In contrast, we
here demonstrated that JUNV infection had no significant effect
on the proliferation, clonogenic ability or maturation of megakar-
yocyte progenitors, but it induced a profound decrease in
proplatelet formation and platelet release. Although impairment
of platelet production has been suggested in HIV patients [37,38],
to the best of our knowledge, this is the first time that a viral
infection has been shown to selectively affect the two last key steps
of thrombopoiesis.
It has recently been demonstrated that TfR1 is the receptor for
some new world arenaviruses, including JUNV [27]. Our results
show that blocking or down-regulating TfR1 surface expression in
CD34
+ cells significantly reduced both JUNV replication as well as
the decrease in platelet formation induced by JUNV infection,
indicating that viral infection is a necessary event for the inhibition
of platelet formation. Moreover, the fact that UV-irradiated virus
had no effect on proplatelet production and platelet release
indicates that viral replication is also necessary to hinder
thrombopoiesis. These data also implicate TfR1 as the main
route of viral entry into hematopoietic progenitor cells. This is
particularly relevant considering that it has recently been shown
that pathogenic strains can use TfR1-dependent or independent
pathways [39]. The observation that JUNV infection up-regulates
TfR1 in CD34
+ cells could represent a viral dissemination strategy
at least in hematopoietic bone marrow cells. However, in vivo
experiments will be required to determine its relevance.
Remarkably, we found that only 5% of total cells were infected,
therefore the observed 50% reduction in platelet production
appeared to be due to a selective bystander effect from infected
cells rather than a direct effect of viral replication on megakar-
yocyte biology. Moreover, poly(I:C), a synthetic analogue of the
dsRNA associated with the replicative cycle of most viruses [28],
mimicked the effect of JUNV infection. Although transfected
poly(I:C) can be sensed by the retinoic induced gene (RIG)-I-like
RNA helicases that stimulate IFN a and b expression, naked
Figure 5. Role of TfR1 in JUNV infection and impaired platelet production. (A) The kinetics of TfR1 expression after JUNV infection in CD34
+
cells stimulated with TPO were determined by flow cytometry. (B) Receptor expression was detected in UV-irradiated JUNV- and JUNV-infected cells
incubated with FITC-anti-CD71 (anti-TfR1) mAb or with a matched isotype control. The histogram depicts a representative flow cytometric analysis of
TfR1 staining after 120 hr of infection. (C) CD34
+ cells were pre-incubated with an anti-CD71, anti-HLA-ABC mAb or ferric ammonium citrate (FAC,
10 mg/ml) for 1 hr (to down-regulate TfR1). Cells were then infected with JUNV and stimulated with TPO and viral antigens were detected by flow
cytometry. The figure shows a representative experiment of three similar replicates. (D) CD34
+ cells were treated as mentioned in C, and also with
deferoxamine (1 mM) for 24 hr (to up-regulate TfR1). Platelets produced in culture were counted at day 15. The values represent the mean 6 SEM of
three independent experiments,* indicates p,0.05 vs. UV-irradiated JUNV, # indicates p,0.05 vs. JUNV.
doi:10.1371/journal.ppat.1000847.g005
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+ cells were treated with poly(I:C) (100 mg/ml) at the
indicated days, stimulated with TPO, and Plt counts were determined at day 15 of the culture. The values represent the mean 6 SEM of four independent
experiments, * p,0.05 vs. vehicle (control). (B) IFN b mRNA levels in UV-irradiated JUNV- or JUNV-infected CD34
+ cells were determined by RT-PCR at the
indicated days of culture. The figure shows a representative experiment of three similar replicates. (C) CD34
+ cells were treated with IFN b and stimulated with
TPO. Plt counts were determined at day 15 of the culture. The values represent the mean 6 SEM of three independent experiments,* indicates p,0.05 vs. no
IFN b, # indicates p,0.05 vs. IFN b (10 U/ml). (D) Total cell number was determined at the indicated days of culture by counting cells with a hemocytometer.
Similar results were obtained in MTT assays. The values represent the mean 6 SEM of three independent experiments. (E) Anti-IFN b (1,000 neutralizing units)
or an equal volume of rabbit Igs was added before CD34
+ cell infection and Plt counts were determined at day 15. Values represent the mean 6 SEM of
three independent experiments, * indicates p,0.05 vs. UV-irradiated JUNV. (F) Type I IFN receptor subunit (IFNAR1 and 2) mRNAs were evaluated by RT-PCR
in megakaryocyte precursors purified by immunomagnetic positive selection (9961% of purity). The figure shows a representative experiment of three similar
replicates. (G) CD34
+ cells were infected with JUNV and 1000 neutralizing units of anti-IFN b or an equal volume of rabbit Igs were added before TPO
stimulation. Viral antigens were detected by flow cytometry. The figure shows a representative experiment of two similar replicates. (H) The kinetics of TfR1
expression in the presence or absence (vehicle) of IFN b (10 U/ml) in CD34
+ cells stimulated with TPO were determined by flow cytometry.
doi:10.1371/journal.ppat.1000847.g006
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the expression of NF-kB and IFN b [40]. Therefore, IFN b
appeared to be a suitable mediator responsible for the reduced
platelet production mediated by JUNV infection of hematopoietic
cells. Our results showing: a) the JUNV-dependent induction of
IFN b mRNA synthesis, b) the suppressive effect of IFN b on
platelet biogenesis, c) the expression of both subunits of the IFN b
receptor in purified megakaryocytes, and d) the reversion of the
inhibitory effect of JUNV on platelet formation with a neutralizing
Ab against IFN b strongly suggest that IFN b is a central mediator
in the JUNV-dependent inhibition of platelet release. Similar
results were obtained with IFN a (data not shown). This would not
be surprising as both IFNs are ligands for the same receptor and
IFN a is a downstream product of IFN b production and signaling
[30]. Furthermore, both cytokines may be the mediators involved
in the bystander effect, and this supports the hypothesis that JUNV
Figure 7. Intracellular mechanisms involved in the JUNV-
induced inhibition of platelet production. CD34
+ cells were UV-
irradiated JUNV- or JUNV-infected, washed and stimulated with TPO. (A)
The Src inhibitor PP2 (10 mM) was added at the indicated days, and Plt
counts were determined at culture day 15. The values represent the
mean 6 SEM of four independent experiments, * indicates p,0.05 vs.
UV-irradiated JUNV-treated cells. (B) Semi-quantitative RT-PCR analysis
of relevant molecules involved in megakaryo/thrombopoiesis were
performed at the indicated days of culture. The figure shows a
representative experiment of three similar replicates. (C) NF-E2
expression was assessed in the megakaryocytic population by
immunostaining the cells first with a PE-conjugated anti-CD41 mAb
or an isotype-matched control. Then the cells were incubated with anti-
NF-E2 polyclonal followed by FITC-conjugated swine anti-rabbit Igs.
Cells were analyzed by flow cytometry. Non-specific fluorescence was
assessed using rabbit serum instead of primary Ab. The values represent
the mean 6 SEM of three independent experiments,* indicates p,0.05
vs. UV-irradiated JUNV-infected cells. The histogram shows a represen-
tative flow cytometric analysis at day ten.
doi:10.1371/journal.ppat.1000847.g007
Figure 8. NF-E2 expression and ultrastructural studies of
megakaryocytes treated with IFN b. (A) After 12 days of CD34
+
cell TPO stimulation, megakaryocytes were purified by immunomag-
netic positive selection (9861% of purity) and NF-E2 expression was
determined two or four days after IFN b (10 U/ml) treatment using the
anti-NF-E2 polyclonal Ab (or rabbit serum) followed by FITC-conjugated
swine anti-rabbit Igs. The values represent the mean 6 SEM of three
independent experiments, * indicates p,0.05 vs. vehicle. (B) Ultrastruc-
ture of megakaryocytes cultured in the presence of vehicle or IFN b
from day seven to day fourteen. Inset in the upper panel shows culture-
derived platelets observed only in vehicle-treated samples.
doi:10.1371/journal.ppat.1000847.g008
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I IFN levels in the bone marrow milieu may result in
thrombocytopenia.
Surprisingly, despite the low number of infected cells, only few
were megakaryocytes. Although we have not yet determined the
identity of the vWF negative-infected cells, they could be
megakaryocytes with low vWF content because it has been
recently shown that treatment of megakaryocytes with IFN a
inhibited 70% of vWF RNA expression [41].
In vivo, JUNV may infect other cells in the bone marrow
environment, and CD34
+ progenitor cells may be exposed to
higher levels of type I IFN than produced in our in vitro system.
Interestingly, we found that while low IFN b concentrations
selectively impaired thrombopoiesis, treatment of CD34
+ cells with
higher concentrations also reduced megakaryocyte numbers
without modifying the apoptosis rate, suggesting an IFN b-
mediated cell cycle arrest. Remarkably, both phenomena were
independently described by different groups using recombinant
IFN a: while Wang et al. demonstrated that IFN a hinders mouse
megakaryopoiesis altering proliferation and ploidy [42], Yamane
et al. found that IFN a decreases platelet production without
altering megakaryocyte growth [41]. Although these findings
appears to be controversial, our results suggest that the levels of
type I IFN in the bone marrow could define the cell fate of
megakaryocytes, affecting either their proliferation or their ability
to produce platelets.
Our analysis of the signaling pathways involved in the JUNV-
mediated inhibition of platelet production indicated that SOCS-
1, SOCS-3, GATA-1, and Src, which are involved in the
processes of proliferation, differentiation, and proplatelet forma-
tion, respectively [31,32,42], were not involved. In contrast,
JUNV-infected samples did show lower levels of both NF-E2
mRNA and protein. Interestingly, we also found that type I IFN
downregulates NF-E2 in megakaryocytes. As this transcription
factor plays a major role in terminal differentiation of
megakaryocytes and platelet release [33], it is conceivable that
the reduced synthesis of NF-E2 mediated by type I IFN may be
one of the molecular pathogenic mechanisms reducing platelet
release in JUNV infection (Figure 9). In fact, thrombocytopenia
driven by recombinant IFN a has been related to the selective
inhibition of cytoplasmic maturation accompanied by downreg-
ulation of the expression of the transcription factors NF-E2,
GATA-1 and MafG/HPRT [41]. Our ultrastructural studies
using IFN b also showed profound alterations in the cytoplasm
that could account for the impaired platelet formation. Addi-
tionally, we also found a lower number of platelet granules in type
I IFN-treated megakaryocytes. Interestingly, NF-E2
2/2 mice
have no circulating platelets and their megakaryocytes present
ultrastructural abnormalities that are quite similar to those of our
type I IFN-exposed megakaryocytes [33].
As regarding type I IFN’s effect on platelet function, elegant
studies from Iannacone et al. revealed that mice infected with
LCMV exhibit a type I IFN-dependent platelet dysfunction that, if
associated with thrombocytopenia below a critical threshold,
results in severe bleeding and acute anemia [43]. Because they did
not observe a direct effect of IFN b on platelet activation, they
suggested that the platelet dysfunction could be the result of a
direct effect of IFN b on parent megakaryocytes or due to the
release from endothelium of platelet inhibitors. Our results
showing that platelets derived from JUNV-infected cultures had
less P-selectin expression upon thrombin stimulation together with
the observation that type I IFN-treated megakaryocytes have
almost no dense or alpha granules strongly support the hypothesis
that megakaryocyte exposure to type I IFN driven by viral
infection of bone marrow cells results not only in a reduced
number of platelets but also in the generation of dysfunctional
platelets. Nevertheless, more studies are required to further
elucidate the hemostatic status and to determine whether similar
structural alterations are observed in platelets from VHF patients.
Do the in vivo data support our hypothesis regarding the critical
role of IFN I in the thrombocytopenia present in VHF patients?
High levels of circulating IFN a that correlate with virulence and
prognosis has been described in different VHF [44–46]. Moreover,
during systemic viral infection, bone marrow hematopoietic cells
appear to be the most important source of type I IFN [47]. In
addition, a direct relationship of thrombocyto/neutropenia driven
by type I IFN was demonstrated in LCMV infected mice. In that
case, however, the condition was mediated by transient bone
marrow aplasia [14]. Overall, these data support a role for type I
IFN as a pathogenic factor for the thrombocytopenia observed in
VHF patients.
In conclusion, we provide the first evidence linking viral infection
of human hematopoietic progenitors with selective inhibition of
thrombopoiesis through the type I IFN pathway. Our studies
highlight a potential mechanism that leads to thrombocytopenia
and bleeding in AHF and other diseases as a result of an increase in
Figure 9. Model of JUNV infection of CD34
+ cells stimulated with TPO. JUNV induces an increase in the expression of TfR1. A very low
proportion of megakaryocytes are infected by JUNV, but the infection triggers type I IFN which impairs proplatelet production, platelet release and
platelet function. The concomitant down-regulation of NF-E2 in the megakaryocytic population may be involved in this effect.
doi:10.1371/journal.ppat.1000847.g009
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should be of use in the effort to find new therapeutic strategies for
the thrombocytopenia that is associated with VHF.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the National Academy of Medicine,
Buenos Aires, Argentina. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Reagents
Fluorescein isothiocyanate (FITC)-conjugated monoclonal an-
tibodies (mAbs) against CD34, glycoprotein (GP) IIb (CD41), GP
Ib (CD42b), P-selectin (CD62p), phycoerytrin (PE)-conjugated
anti-GP IIIa (CD41), unconjugated anti-human HLA-ABC, anti-
CD71 Abs, and a fixation/permeabilization kit (BD Cytofix/
Cytoperm
TM) were purchased from BD Biosciences (Franklin
Lakes, NJ). FITC-conjugated anti-rabbit immunoglobulins (Igs)
and anti-von Willebrand factor (vWF) Abs were obtained from
Dako A/S (Glostrup, Denmark). Cy3-conjugated anti-mouse Ig
was obtained from Zymed (San Francisco, CA). Recombinant
human IFN a2b and rabbit polyclonal anti-human IFN b
neutralizing Ab were obtained from Pestka Biomedical Labora-
tories (Piscataway, NJ). Rabbit polyclonal IgG anti-NF-E2 Ab was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Random hexamers, SuperScript III reverse transcriptase and
Trizol were from Invitrogen. The synthetic analog of dsRNA
polyriboinosinic polyribocytidylic acid, poly(I:C) and recombinant
human IFN b1a were obtained from InvivoGen (San Diego, CA).
The Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine (PP2) was obtained from Biomol
International LP (Plymouth Meeting, PA). Thrombopoietin (TPO)
was obtained from Peprotech (Veracruz, Mexico). All of the other
reagents were obtained from Sigma Chemical Co. (St. Louis, MO).
Isolation of CD34
+ cells
Isolation of CD34
+ cells was performed as previously described
[48]. Briefly, human umbilical cord blood was collected during
normal full-term deliveries and was used within 24 hr. After
collection, samples were diluted one to three with PBS and
centrifuged to remove platelets. Low density mononuclear cells
were prepared by centrifugation of the remaining blood over a
Ficoll Hypaque. Cells collected from the interface were washed,
and CD34
+ cells were purified using a magnetic cell-sorting system
(Miltenyi Biotec, Bergisch Gladbach, Germany) in accordance
with the manufacturer’s recommendations. After two Mini-MACS
column separations, the purity of the cell suspension was
determined by flow cytometry and typically ranged between 95
and 99%. Cell viability was greater than 90%. Fresh CD34
+ cells
were used for each experiment.
Purification of megakaryocytes
Mature megakaryocytes were purified by immunomagnetic
positive selection from TPO-stimulated CD34
+ cultures on day 12
using anti-CD41 magnetic beads (Miltenyi Biotec) following the
manufacturer’s instructions. The purity of the final cell suspension
was $95% and cell viability was greater than 80%.
Vero-76 cells
Monolayers of Vero-76 cells (CRL-1587, the American Type
Culture Collection (ATCC), Manassas, VA) were grown in
minimum essential medium (MEM) containing 10% fetal calf
serum (FCS) and antibiotics.
Virus
A virulent strain of JUNV originally isolated from an AHF
patient (P3441) was kindly provided by Dr. A. Ambrosio of the
Instituto Nacional de Enfermedades Virales Humanas ‘‘Dr. Julio I.
Maiztegui’’, Pergamino, Argentina. Virus stocks were grown,
identified, and quantified as described previously by using the
JUNV-susceptible Vero-76 cell line. Virulence was tested in three-
week-old guinea pigs and the median lethal dose, (LD50), assayed
between 11 and 14 days p.i., was #10 PFU. When required, virus
was subjected to UV inactivation for 20 min using a 365 nm UV
bulb positioned 5 cm over the stock [49].
Cell infection
CD34
+ cells (1610
4) or a monolayer of Vero-76 cells were
inoculated with JUNV at a multiplicity of infection (MOI) of one
or the equivalent volume of UV-irradiated virus for 1 hr at 37uC.
Mock-infected controls contained supernatants of Vero cells
instead of JUNV. After washing, UV-irradiated JUNV-, JUNV-
or mock-infected CD34
+ cells were cultured in Iscove’s Modified
Dulbecco’s Medium (IMDM, HyClone) containing 2 mM gluta-
mine, 5% human serum (obtained by re-calcification of citrated
platelet-free plasma), 25 ng/ml TPO and antibiotics (growth
medium) at 37uC in a humidified atmosphere with 5% CO2 [50].
Fresh TPO (25 ng/ml) was added at day seven. Vero-infected cells
were cultured for seven days in MEM containing 2% FCS and
antibiotics.
Detection of JUNV proteins
Cells were washed with PBS (Ca
2+- and Mg
2+-free), cytocen-
trifuged on silanized glasses, fixed with 1% paraformaldehyde
(PFA) for 20 min and permeabilized with 0.1% Tween for 10 min.
The slides were incubated overnight at 4uC with a pool of specific
mAbs against JUNV [22] and a rabbit-anti-human vWF
polyclonal Ab to identify megakaryocytes. FITC-conjugated anti-
rabbit and Cy3-conjugated anti-mouse Igs were then applied to
the PBS-washed slides for 30 min at room temperature (RT). Abs
were diluted with PBS containing 5% fetal bovine serum and 5%
goat serum as blocking agents. The slides were counterstained with
DAPI and examined under an Olympus BX60 microscope
equipped with a 1006PlanApo objective (NA 1.4) and a 100-W
mercury lamp. Images were acquired with an Applied Imaging
Model 4912–5010/0000 charge coupled device (CCD) camera.
Electron image acquisition was under the control of Cytovision
software.
For flow cytometric studies, samples were washed, fixed with
1% PFA for 20 min, and permeabilized with 0.1% saponin for
10 min. Cells were then incubated for 1 hr at RT with a pool of
specific mAbs against JUNV and a rabbit-anti-human vWF
polyclonal Ab. After two washes, FITC-conjugated anti-rabbit and
Cy3-conjugated anti-mouse Igs were diluted in 0.1% saponin and
added to the samples for 30 min and analyzed on a FACSCalibur
flow cytometer using CellQuest software (BD Biosciences).
Negative controls were performed using uninfected cells or
omitting primary Abs. JUNV-susceptible Vero cells were used as a
positive control.
Evaluation of megakaryocyte development
The levels of CD34, CD41 and CD42b in the TPO-stimulated
CD34
+ cell cultures were measured by immunostaining with
saturating concentrations of specific FITC-labeled mAbs or an
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30 min of incubation, the samples were fixed with 1% PFA and
analyzed by flow cytometry.
To evaluate megakaryocyte ploidy, cells were centrifuged for
10 min at 2206g, washed and fixed in 70% ethanol at 220uC
overnight. Cells were then washed, resuspended in PBS, and
incubated for 30 min at RT with saturating concentrations of
FITC-conjugated anti-CD41 (or isotype control), 1 mg/ml propi-
dium iodide, and 10 U/ml RNaseA. Cell ploidy was analyzed by
flow cytometry.
Clonogenic progenitor assays
Aliquots of 5610
3 CD34
+ cells were resuspended in collagen-
based, serum-free medium containing 50 ng/ml TPO (MegaCult,
Stem Cell Technology, Vancouver, Canada) and seeded in
double-chamber culture slides. After 12 days, megakaryocyte
colonies were detected using an anti-CD41 antibody and an
alkaline phosphatase detection system and were then counter-
stained with Evan’s Blue. Two categories of colonies were
identified: pure megakaryocyte colonies and mixed megakaryocyte
colonies (distinguished by the presence of non-megakaryocyte cells
within the same colony). Pure megakaryocyte colonies were scored
according to their size: small CFU-megakaryocytes (3–20 cells),
medium CFU- megakaryocytes (20–50 cells), and large CFU-
megakaryocytes (.50 cells).
Proplatelet formation (PPF)
PPF was analyzed as previously described with some modifica-
tions [51]. Twelve-mm glass coverslips were coated with 100 mg/
ml fibrinogen for 2 hr at RT and subsequently blocked with 1%
bovine serum albumin for 1 hr. Cells cultured for 12 days were
harvested, plated on coated coverslips in 24-well plates (1610
5
cells per well) and allowed to adhere for 4 hr at 37uC and 5%
CO2. PPF was then evaluated by fluorescence microscopy by
staining cells with TRITC-conjugated phalloidin. DAPI was used
as a counterstain. Proplatelet-forming megakaryocytes were
identified as large cells exhibiting long filamentous structures.
The extent of PPF was calculated as the percentage of proplatelet-
bearing cells by counting 500 cells per treatment.
Determination of platelet number produced in culture
Platelets were counted using flow cytometry as previously
described [25]. Briefly, cells were incubated with a FITC-labeled
anti-CD41 mAb for 15 min and fixed with 1% PFA for 20 min.
Cells from each culture condition were distributed in the same
volume. For each sample, the acquisition rate was 1 ml/sec for
100 sec. Events were collected without gating using a log scale for
size (FSC) and intracellular granularity (SSC). An analytical gate
was determined based on the scatter properties of normal blood
platelets treated similarly to the culture-derived platelets. This gate
excluded large contaminating cells and small debris or micropar-
ticles. Culture-derived platelets were counted as CD41
+ events
with the same scatter properties as blood platelets.
P-selectin expression on in vitro-produced platelets
P-selectin expression on platelets was determined as previously
described with minor modifications [52]. Briefly, culture-derived
platelets were isolated by centrifugation at 10006g in the presence
of PGI2 to avoid platelet preactivation. The pellet was resuspended
in modified Tyrode buffer (134 mM NaCl; 2.9 mM KCl;
0.34 mM Na2HPO412H2O; 12 mM NaHCO3; HEPES 20 mM;
MgCl2 1 mM; glucose 5 mM, pH 7.3) and left to rest for 30 min
at 37uC. The suspension was stimulated with 1 U/ml thrombin for
10 min at 37uC. After fixation, cells were stained with anti–P-
selectin (CD62p)–FITC and anti-CD41-PE mAbs for 30 min and
P-selectin expression was measured by flow cytometry using the
characteristic forward and side scatter pattern of normal blood
platelets treated similarly.
Expression of TfR1 and NF-E2
To determine the level of TfR1 expression on TPO-stimulated
CD34
+ cell membranes, cells were incubated with a FITC-
conjugated anti-CD71 or an isotype-matched control mAb at the
indicated days p.i. Samples were washed, fixed, and analyzed by
flow cytometry.
CD34-derived megakaryocytes were tested for NF-E2 expres-
sion using a double-labeling technique (NF-E2/CD41). Cells were
immunostained with a PE-conjugated anti-CD41 mAb or an
isotype-matched control and fixed with 1% PFA at 4uC. After
washing with PBS containing 0.1% saponin, cells were incubated
first for 30 min in the same buffer with anti-NF-E2 polyclonal Ab
at 4uC and then with FITC-conjugated swine anti-rabbit Igs. Cells
were analyzed by flow cytometry. Non-specific fluorescence was
assessed using rabbit serum instead of primary Ab. In selected
experiments, NF-E2 expression was determined in purified mature
megakaryocytes treated with type I IFN using the anti-NF-E2
Table 1. Primers used for RT-PCR (59R39).
Gene Fragment size (bp) Forward Reverse
JUNV 640 CGCACCGGGGATCCTAGGC GGCATWGANCCAAACTGATT
IFN a 274 TCCATGAGATGATCCAGCAG ATTTCTGCTCTGACAACCTCCC
IFN b 286 GCTCTCCTGTTGTGCTTCTCCAC CAATAGTCTCATTCCAGCCAGTGC
IFNAR1 326 GTGATACACATCTCTCCTGG GTATAATCCCATTTAAGAACATAG
IFNAR2 394 GAGTAAACCAGAAGATTTGAAG CGTGTTTGGAATTAACTTGTC
NF-E2 255 CAGTAGGATGTCCCCGTGTC TAAGGTGGTGGAGGAAGTGG
GATA-1 613 ATTGTCAGTAAACGGGCAGG GCTTTGAAGGTTCAAGCCAG
SOCS-1 562 AGAGCTTCGACTGCCTCTT AGGTAGGAGGTGCGAGTTCA
SOCS-3 554 CTCAAGACCTTCAGCTCCAA TTCTCATAGGAGTCCAGGTG
GAPDH 996 GTGAAGGTCGGAGTCAACG TCCTTGGAGGCCATGTGGGCCCT
The following symbols were used for mixed bases: W, A:T; N, A:C:G:T.
doi:10.1371/journal.ppat.1000847.t001
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swine anti-rabbit Igs.
RNA isolation and semi-quantitative RT-PCR
Total RNA was isolated from cell pellets using Trizol as
recommended by the manufacturer. cDNA was synthesized from
20 ng of total RNA using 15 mM of random hexamers and
SuperScript III reverse transcriptase according to the manufac-
turer’s instructions. The cDNA samples were diluted 10-fold, and
the PCR reaction was conducted at the annealing temperature of
55uC. All reactions were confirmed to be within the linear range of
amplification. The primer sequences and sizes of the amplified
fragments are included in Table 1.
Thin-section electron microscopy
Megakaryocytes were fixed with 1.5% glutaraldehyde in 0.1 M
cacodylate buffer, pH 7.4, for eight hr. Cells were dehydrated
through a series of alcohols, infiltrated with propylene oxide, and
embedded in epoxy resin in an inverted beam capsule. Ultrathin
sections were stained with uranyl acetate and lead citrate and
examined with a Tecnai G2 Spirit BioTWIN transmission electron
microscope (Hillsboro, OR) at an accelerating voltage of 80 kV,
and images were recorded with an AMT 2k CCD camera
(Danvers, MA).
Statistical analysis
All results are expressed as the means 6 SEM. Student’s paired
t test was used to determine the significance of differences between
means, and p values lower than 0.05 were considered to be
statistically significant. When multiple groups were compared,
one-way analysis of variance (ANOVA) followed by the Newman-
Keuls procedure was used to determine significant differences
between groups.
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